Pictet Asset Management Ltd. Buys 92,725 Shares of CytomX Therapeutics Inc (CTMX)
Pictet Asset Management Ltd. increased its stake in shares of CytomX Therapeutics Inc (NASDAQ:CTMX) by 17.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 617,209 shares of the biotechnology company’s stock after acquiring an additional 92,725 shares during the quarter. Pictet Asset Management Ltd. owned approximately 1.37% of CytomX Therapeutics worth $11,418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of CTMX. Great West Life Assurance Co. Can lifted its holdings in CytomX Therapeutics by 174.6% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock worth $113,000 after buying an additional 3,143 shares during the period. SG Americas Securities LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter worth approximately $119,000. Capital Fund Management S.A. purchased a new stake in CytomX Therapeutics in the 2nd quarter worth approximately $247,000. Tiff Advisory Services Inc. purchased a new stake in CytomX Therapeutics in the 2nd quarter worth approximately $320,000. Finally, Fox Run Management L.L.C. purchased a new stake in CytomX Therapeutics in the 3rd quarter worth approximately $225,000. Institutional investors and hedge funds own 83.79% of the company’s stock.
In related news, insider Sean A. Mccarthy sold 6,526 shares of the firm’s stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $15.00, for a total transaction of $97,890.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Debanjan Ray sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $18.46, for a total value of $55,380.00. Following the transaction, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at approximately $164,810.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,526 shares of company stock valued at $198,270. 8.50% of the stock is currently owned by company insiders.
CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.11). The firm had revenue of $12.51 million during the quarter, compared to analysts’ expectations of $16.42 million. CytomX Therapeutics had a negative net margin of 68.90% and a negative return on equity of 65.03%. As a group, analysts expect that CytomX Therapeutics Inc will post -1.78 earnings per share for the current year.
Several equities research analysts have weighed in on CTMX shares. HC Wainwright started coverage on CytomX Therapeutics in a report on Thursday, September 13th. They issued a “buy” rating and a $32.00 price objective for the company. ValuEngine cut CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 29th. Cowen began coverage on CytomX Therapeutics in a research note on Monday, November 12th. They issued a “buy” rating for the company. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Finally, Cann restated a “hold” rating on shares of CytomX Therapeutics in a research note on Tuesday, November 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. CytomX Therapeutics currently has a consensus rating of “Buy” and an average price target of $32.47.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Recommended Story: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.